EDU 22 - Endometrial and Cervical Cancer Case Discussion on Utilizing Molecular Data for Treatment Decisions
MODERATOR(S)
Katherine Tzou, MD - University of Colorado
session DESCRIPTION
Using a case-based approach, this session will discuss recent data and how to incorporate molecular data for treatment risk stratification and follow up for endometrial and cervical cancer patients. The cervix cancer case discussion will highlight how HPV ctDNA can be a tool for early recurrence detection and will also cover the recently published CALLA data showing how ctDNA predicted relapse and survival outcomes. The early-stage endometrial cancer case discussion will cover the PORTEC2 molecular data, the more recently identified significance of MLH1 promoter hypermethylation and the newly published PORTEC4 results. The session will also include a comparing and contrasting of the PORTEC 3 and more recently published GOG 258 molecular data using an advanced endometrial case discussion to help highlight how to utilize molecular data to optimize treatment approach.
learning objectives
- Be able to discuss how pathologic factors, such as molecular status, influence prognosis and treatment decisions.
- Discuss recent clinical trial data where molecular data was used for risk stratification or influenced gynecologic cancer patient outcomes.
- Describe how ctDNA can potentially be used to follow cervical cancer patients.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
10:45am - 10:47am ETSpeaker: Katherine Tzou, MD - University of Colorado , Colorado Springs
-
10:47am - 11:07am ETSpeaker: Kathy Han, MD, MS - Princess Margaret Cancer Center, University Health Network, Toronto
-
11:07am - 11:27am ETSpeaker: Lara Hathout, MD, FRCPC - Rutgers Cancer Institute , New Brunswick
-
11:27am - 11:47am ETSpeaker: Shari Damast, MD - Yale University, New Haven
-
11:47am - 12:00pm ETSpeaker: Katherine Tzou, MD - University of Colorado , Colorado Springs